Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.
Alpha Cognition and China Medical System sign a $44M licensing deal for Zunveyl. ALPHA-1062 preclinical data shows benefits for blast-related brain injuries.
With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
Alpha Cognition (ACOG) announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; ...
The agreement with China Medical System Holdings Limited is for the development, manufacturing, and commercialization of ...
These hires mark significant milestones in building Alpha Cognition’s commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better ...